The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Proscia Secures $50M Funding for AI-Driven Pathology Platform and Precision Medicine
Mar 19, 2025•about 1 year ago
Contract Type
partnership
PhiladelphiaInformation TechnologySoftware
Description
Proscia has secured $50M in funding to advance its AI-driven pathology platform, Concentriq, and its mission to revolutionize precision medicine. The company is on track for significant growth, with 16 of the top 20 pharmaceutical companies among its users and a goal of diagnosing 22,000+ patients daily on its software platform. The funding will enable Proscia to further drive the modernization of pathology and fulfill the growing demand for advanced diagnostics and digital pathology.
Company Information
Company
Proscia
Location
1700 MARKET STREET
Philadelphia, Pennsylvania, United States
About
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer. 16 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia’s solutions each day. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software.
PhiladelphiaInformation TechnologySoftware